Advantage Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Advantage Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$35K	Sell	205 -72	-26%	-$12.7K	0.03%	406
2019 Q2	$51K	Sell	277 -4	-1%	-$699	0.04%	341
2019 Q1	$52K	Sell	281 -147	-34%	-$27.2K	0.04%	343
2018 Q4	$71K	Buy	428 +14	+3%	+$2.43K	0.05%	284
2018 Q3	$80K	Buy	+414	New	+$73.7K	0.05%	314

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Advantage Investment Management's VRTX Position: Q3 2019 in Review

Advantage Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 26% in Q3 2019, selling an estimated $12.7K and leaving 205 shares worth $35K. The position accounts for 0.03% of the portfolio, ranked #406.

Advantage Investment Management first reported a position in VRTX in Q3 2018 and has held it in 5 quarters since. The position peaked at $80K in Q3 2018. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Advantage Investment Management held 205 shares of Vertex Pharmaceuticals worth $35K as of Q3 2019.
Advantage Investment Management sold 72 Vertex Pharmaceuticals shares in Q3 2019, an estimated $12.7K.
Vertex Pharmaceuticals made up 0.03% of Advantage Investment Management's portfolio in Q3 2019, its #406 holding.
Advantage Investment Management first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 5 quarters since.
Advantage Investment Management's Vertex Pharmaceuticals position peaked at $80K in Q3 2018.
708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.